EP2773336A4 - METHODS OF TREATING HYPERURICEMIA IN DROPPING PATIENTS USING HALOFENATE OR HALOFENIC ACID AND SECOND URATIC REDUCING AGENT - Google Patents

METHODS OF TREATING HYPERURICEMIA IN DROPPING PATIENTS USING HALOFENATE OR HALOFENIC ACID AND SECOND URATIC REDUCING AGENT

Info

Publication number
EP2773336A4
EP2773336A4 EP11875114.8A EP11875114A EP2773336A4 EP 2773336 A4 EP2773336 A4 EP 2773336A4 EP 11875114 A EP11875114 A EP 11875114A EP 2773336 A4 EP2773336 A4 EP 2773336A4
Authority
EP
European Patent Office
Prior art keywords
halofenate
urate
gout
patients
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11875114.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2773336A1 (en
Inventor
Brian K Roberts
Gopal Chandra Saha
Brian Edward Lavan
Charles A Mcwherter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diatex Inc
CymaBay Therapeutics Inc
Original Assignee
Metabolex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolex Inc filed Critical Metabolex Inc
Publication of EP2773336A1 publication Critical patent/EP2773336A1/en
Publication of EP2773336A4 publication Critical patent/EP2773336A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP11875114.8A 2011-11-04 2011-11-04 METHODS OF TREATING HYPERURICEMIA IN DROPPING PATIENTS USING HALOFENATE OR HALOFENIC ACID AND SECOND URATIC REDUCING AGENT Withdrawn EP2773336A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059394 WO2013066349A1 (en) 2011-11-04 2011-11-04 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent

Publications (2)

Publication Number Publication Date
EP2773336A1 EP2773336A1 (en) 2014-09-10
EP2773336A4 true EP2773336A4 (en) 2015-06-03

Family

ID=48192533

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11875114.8A Withdrawn EP2773336A4 (en) 2011-11-04 2011-11-04 METHODS OF TREATING HYPERURICEMIA IN DROPPING PATIENTS USING HALOFENATE OR HALOFENIC ACID AND SECOND URATIC REDUCING AGENT

Country Status (13)

Country Link
EP (1) EP2773336A4 (enExample)
JP (1) JP6202633B2 (enExample)
KR (1) KR20140121383A (enExample)
CN (2) CN104066427A (enExample)
AU (1) AU2011380507B2 (enExample)
CA (1) CA2859686C (enExample)
CL (1) CL2014001155A1 (enExample)
IL (1) IL232386A0 (enExample)
MX (1) MX357507B (enExample)
NZ (1) NZ624708A (enExample)
SG (1) SG11201402032RA (enExample)
WO (1) WO2013066349A1 (enExample)
ZA (1) ZA201403575B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104602686A (zh) * 2012-04-13 2015-05-06 西玛贝医药公司 利用卤芬酯或卤芬酸以及抗炎剂治疗痛风患者中高尿酸血症的方法
TWI705812B (zh) * 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
JP6368756B2 (ja) * 2016-10-20 2018-08-01 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
CN108014108A (zh) * 2016-11-03 2018-05-11 江苏万邦生化医药股份有限公司 lesinurad或其医药上可接受的盐在制备治疗或预防库欣综合征的药物中的应用
EP3701952A4 (en) * 2017-10-26 2021-06-30 Otsuka Pharmaceutical Co., Ltd. INOSITE PHOSPHATE COMPOSITION
JP2023525631A (ja) * 2020-03-15 2023-06-19 アレン ダビドフ ウイルス感染症及び健康上の影響の治療方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130172368A1 (en) * 2011-11-04 2013-07-04 Metabolex, Inc. Methods for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halogenic Acid and A Second Urate-Lowering Agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
WO2011032175A1 (en) * 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130172368A1 (en) * 2011-11-04 2013-07-04 Metabolex, Inc. Methods for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halogenic Acid and A Second Urate-Lowering Agent

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "NCT01399008 on 2011_07_20: ClinicalTrials.gov Archive", 20 July 2011 (2011-07-20), XP055185403, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT01399008/2011_07_20> [retrieved on 20150423] *
ANONYMOUS: "NCT01416402 on 2011_10_21: ClinicalTrials.gov Archive", 21 October 2011 (2011-10-21), XP055185406, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT01416402/2011_10_21> [retrieved on 20150423] *
GOPAL C SAHA ET AL: "Arhalofenate, a Potential Novel Treatment for Hyperuricemia, with or without Metabolic Co-Morbidities, in Patients with Gout: Meta-Analysis of Urate Lowering in Four Phase 2 Studies in Type 2 Diabetes.", ARTHRITIS & RHEUMATISM, vol. 63, no. 10, Suppl. S, October 2011 (2011-10-01), pages S1014, XP055185501 *
HOWARD S SMITH ET AL: "Gout: Current Insights and Future Perspectives", JOURNAL OF PAIN, vol. 12, no. 11, 28 September 2011 (2011-09-28), pages 1113 - 1129, XP028334440, ISSN: 1526-5900, [retrieved on 20110704], DOI: 10.1016/J.JPAIN.2011.06.009 *
See also references of WO2013066349A1 *

Also Published As

Publication number Publication date
MX2014005400A (es) 2015-02-12
CA2859686C (en) 2018-09-11
EP2773336A1 (en) 2014-09-10
AU2011380507B2 (en) 2017-06-15
AU2011380507A1 (en) 2014-05-29
JP2014532758A (ja) 2014-12-08
CN109908124A (zh) 2019-06-21
CA2859686A1 (en) 2013-05-10
CL2014001155A1 (es) 2015-01-16
IL232386A0 (en) 2014-06-30
CN104066427A (zh) 2014-09-24
NZ624708A (en) 2015-11-27
JP6202633B2 (ja) 2017-09-27
MX357507B (es) 2018-07-12
ZA201403575B (en) 2015-11-25
WO2013066349A1 (en) 2013-05-10
KR20140121383A (ko) 2014-10-15
SG11201402032RA (en) 2014-09-26

Similar Documents

Publication Publication Date Title
EP2716669A4 (en) METHOD OF MODIFYING SURFACE AND ELASTIC BODY HAVING MODIFIED SURFACE
EP2627331A4 (en) METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES
EP2714172C0 (en) DEPLOYMENT MECHANISM FOR BODY VESSEL INSERTION DEVICES
EP2788075A4 (en) DEVICE AND METHOD FOR REDUCING THE TRANSTHORACOID IMPEDANCE OF A PATIENT
PT3257546T (pt) Método de preparação de cateter urinário pronto a utilizar
SG11201401811WA (en) Method for preventing and/or treating insulin resistance
AP2013007249A0 (en) Benzothiazole compounds and their pharmaceutical use
ZA201300055B (en) Treatment of gout and hyperuricemia
DK2750705T3 (en) Methods for effectively and rapidly desensitizing allergic patients
PT2663864T (pt) Método de avaliação de imunodiversidade e seu uso
EP2739352A4 (en) MULTIMODAL ELECTROTHERAPY PROCESS AND DEVICE
FI20115893L (fi) Menetelmä retention säätämiseksi ja menetelmässä käytettävä välituote
PT2717692T (pt) Ácidos tetra-hidrocanabinol-11-oicos para utilização no tratamento de doenças fibróticas
ZA201307742B (en) Method for manufacturing and utilizing ferritic-austenitic stainless steel
ZA201403575B (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
EP2682248A4 (en) INJECTION-FORMED BODY AND METHOD OF MANUFACTURING THE SAME
ZA201304353B (en) Remedial composition and treatment methods
SG11201401272RA (en) Method for manufacturing acrylic acid-based polymer and use for same
SG11201406495UA (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
EP2863602A4 (en) ENGINEER AND METHOD FOR CORRECTING SQUARE ERRORS
IL232385A (en) Use of Halopnate or Cephalic Acid Compounds to Treat Hyperoricemia in Patients with Gout, Hyperoricemia, or Renal Disorder
EP2640376A4 (en) CAFFEINE ACID DERIVATIVES AND THEIR USE FOR IMPROVING NEURONAL CELL-LIFECITY
EP2773261A4 (en) PRESSURE GAUGE FOR TESTING THE SPINAL REGION AND METHOD THEREOF
SG10201609202PA (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
ZA201404738B (en) Treatment of type i and type ii diabetes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140522

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150506

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/19 20060101AFI20150428BHEP

Ipc: A61K 31/426 20060101ALI20150428BHEP

Ipc: A61P 19/06 20060101ALI20150428BHEP

Ipc: A61K 31/519 20060101ALI20150428BHEP

Ipc: A61K 31/216 20060101ALI20150428BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CYMABAY THERAPEUTICS, INC.

Owner name: DIATEX, INC.

17Q First examination report despatched

Effective date: 20180115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20190603